SCHEMBL4615436

SCHEMBL4615436

CCCCn1c(=O)[nH]c(=O)c2[nH]c(C(Cc3ccccc3F)c3ccc(NS(=O)(=O)c4ccc(OC)cc4)cc3)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
PCK1 P35558 5/20 0.41
ADORA2B P29275 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
PGR P06401 1/20 0.37
ADORA2A P29274 2/20 0.36
MAPT P10636 2/20 0.36
BRD4 O60885 1/20 0.35
GAA P10253 1/20 0.35
PDE5A O76074 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4614552 0.94 PCK1 (0.44) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614662 0.93 PCK1 (0.42) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614527 0.93 PCK1 (0.41) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4615595 0.92 PCK1 (0.42) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614819 0.92 PCK1 (0.43) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614679 0.92 PCK1 (0.44) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4613809 0.92 PCK1 (0.41) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614787 0.92 PCK1 (0.41) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL6276453 0.91 MEN1 (0.42) KDM4EMEN1ALDH1A1KMT2ALMNA
SCHEMBL4614713 0.91 MEN1 (0.42) KDM4EMEN1ALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US claimed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US claimed
EP-1599477-B1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-30 EP disclosed
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US disclosed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192708-A1 Sulfonamide substituted xanthine derivatives GYS2, SLC5A1, SLC5A2 KDM4E 2503/4885MEN1 3211/4885ALDH1A1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.